1 / 1

SAF32

Characterization of bovine and human cellular prion protein expressed in the central nervous system and in lymphoid organs.

Télécharger la présentation

SAF32

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Characterization of bovine and human cellular prion protein expressed in the central nervous system and in lymphoid organs Prion cell tropism significantly varies among animal species, depending on both the agent strain and host-specific factors. For example, prions show high lymphotropism in scrapie infected sheep and in vCJD, but little, if any, in sCJD or BSE. In particular, the BSE strain is associated with significant PrP-res accumulation in tonsils, spleen and appendix in humans, whereas, it is largely confined to the nervous system in infected cattle. So, it appears that, at least in the case of BSE and vCJD, host properties can influence the accumulation of the infectious agent in lymphoid organs. Given that the normal cellular prion protein (PrPc), is sine qua non for PrP-res formation and the development of TSE, it appears reasonable to hypothesize that tissue-specific PrPc properties may represent one of the host factors influencing the cell tropism of the infectious agent in human or bovine. SAF60 SAF60 SAF32 SAF32 SAF32 SAF32 V. Defaweux1, S. Capellari2, S. Stramiello2, N. Antoine3, G. Dorban1, C. Demonceau1, O. Jolois1, E. Heinen1 and P. Parchi2. 1Dpt of Morphology and Immunology, Institute of Human Histology, Faculty of Medecine, University of Liège, Belgium–www.ulg.ac.be/histohum. 2Department of Neurological Sciences, Faculty of Medicine, University of Bologna, Italy. 3Laboratoy of Animal Histology, Department of Morphology and Pathology, Faculty of Veterinary Medecine, University of Liège, Belgium. Western blot analysis of truncated PrPc forms expressed in bovine CNS Western blot analysis to compare the ratio of PrPc glycoforms expressed in the CNS of bovine and human • PrPc glycoform ratios are significantly different between cerebellum and medulla in bovine and human. • Only the unglycosylated PrPc is distributed like wise in medulla and in the cerebellum of bovine and human. • The expression of truncated forms of PrPc (i.e. 21 and 18 kDa PrPc) is also significantly heterogenous according to the brain region investigated. Western blot analysis to compare the PrPc glycoform ratios and the truncated PrPc forms expressed in bovine lymphoid tissuesin bovine lymhpoid cells Isolation of PrPc expressing follicular dendritic cells (FDC) FDC ultrastructure SAF32+ FDC • PrPc is highly glycosylated in spleen and in lymphoid follicles isolated from bovine lymphoid tissues as well as in their FDC and lymphocytes. • After deglycosylation, a novel PrPc truncated form with a relative molecular mass of about 25 kDa was detected in bovine lymphoid organs beside the typical 18 and 21 kDa forms. Western blot analysis to compare the PrPc glycoform ratios and the truncated PrPc forms expressed in human lymphoid tissues Our results highlight variation in the profile expression of PrPc in peripheral and central tissues of bovine and human. Such differences may have an implication for PrPc function and may represent critical factors influencing the accumulation of the infectious agent in these areas. • No difference in WB PrPc profile was seen in follicles, lymphocytes and FDC of human tissues • Immune PrPc is highly glycosylated and, after deglycosylation, the 25 kDa is also expressed in human lymphoid tissues and cells. Supported by the EU contract QLG3-CT-2002-81030

More Related